FundingWatcher
Home / Startups / Top biotech startups / Biotech startups in Shanghai, China

Biotech startups in Shanghai, China

Updated 16 Nov 2026

Reset
Biotech startups in Shanghai, China
One-time CSV
  • 229 funded companies, 153 with a website
  • Last round, amount, date, total raised and investors
  • CRM-ready CSV, 18 columns
  • Download right after payment
With founder contacts
Compiled to order
  • The full startup CSV, plus founders and executives
  • Up to 2 founders or CEOs per company, compiled to order
  • Name, job title and LinkedIn URL where found
  • Verified direct email per person
  • Startup CSV at once, contacts CSV by mail within 24 hours
Download right after paymentFree 10-row sampleSecure checkout by Stripe

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

startups-biotech~shanghai-shanghai.csv229 rows × 18 columns
CompanyCityLast roundAmountDate
EnjosimShanghaiSeries B$30.1M2026-11-02
Drug FarmShanghaiSeries D$55.0M2026-07-13
Degron TherapeuticsShanghaiSeries A$40.0M2026-05-14
MindRank AIShanghaiSeries B$52.0M2026-07-08
Bluesail SurgicalShanghaiSeries B$104.5M2026-09-23
Full-Life TechnologiesShanghaiSeries D$109.0M2026-05-18
Phrontline BiopharmaShanghaiSeed$60.0M2025-11-21
BivisionShanghaiSeries B$58.8M2026-05-18

8 rows of the CSV in 5 of its 18 columns.

229
Startups
$8.0B
Total raised
40
Funded in the last 12 months
$1.6B
Raised in the last 12 months

Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.

Newest rounds

16 of 229
16 rows
Company What they do Sector Last round Amount Date Total raised Investors Employees Founded
Enjosim Enjosim researches, manufactures, and sells self-delivery systems for biomacromolecule pharmaceuticals. Biotech Series B $30.1M 2026-11-02 $30.1M Luminous Ventures (former Lightspeed China Partners), Jiayuan Capital 51 to 100 2021
Bluesail Surgical Bluesail Surgical develops surgical instruments for cardiovascular treatments. Biotech Series B $104.5M 2026-09-23 $245.4M Huagai Capital, Linkong Private Equity Fund Management, Linqu County High-Tech Industrial Investment 101 to 250 2020
Drug Farm Drug Farm develops therapies for infectious, immunological, and inflammatory diseases using genetics and artificial intelligence. Artificial intelligence Series D $55.0M 2026-07-13 $138.0M DT Capital Partners, South China Venture Capital, BVCF +1 101 to 250 2015
MindRank AI MindRank AI develops artificial intelligence platforms to discover and develop small molecule drugs. Artificial intelligence Series B $52.0M 2026-07-08 $101.0M Green Pine Capital Partners, Huagai Capital, Sherpa Healthcare Partners +1 11 to 50 2020
SynMetaBio SynMetaBio develops synthetic biological materials by combining synthetic biology with material design. Biotech Series A $14.7M 2026-07-06 $16.1M MiraclePlus, Linear Capital, Danen Capital 11 to 50 2021
Full-Life Technologies Full-Life Technologies develops, produces, and commercializes medicines for cancer therapy. Biotech Series D $109.0M 2026-05-18 $337.3M Sky9 Capital, Chengwei Capital, Prosperity7 Ventures +1 51 to 100 2021
Bivision Bivision researches and develops targeted radiopharmaceuticals for therapy. Biotech Series B $58.8M 2026-05-18 $100.9M Gaorong Capital, Kaitai Capital, Lichen Capital 11 to 50 2021
Degron Therapeutics Degron Therapeutics discovers molecular glue degraders for cancer treatment. Biotech Series A $40.0M 2026-05-14 $94.0M Baidu Ventures, BioVenture, New Alliance Capital +2 101 to 250 2021
Novamab Novamab researches and develops new nanobodies. Biotech Series B $43.9M 2026-04-24 $97.8M Qiming Venture Partners, Taiyu Investment, Fuho Capital +1 51 to 100 2017
CORXEL Pharmaceuticals CORXEL Pharmaceuticals develops medicines for underserved patients. Biotech Series D $287.0M 2026-01-22 $451.8M Leaps by Bayer, RTW Investments 51 to 100 2019
Alioth Alioth develops and applies technical products for pharmaceutical process technology. Biotech Series B $14.4M 2026-01-15 $54.7M Matrix Partners China, Legend Capital 51 to 100 2021
Allink Biotherapeutics Allink Biotherapeutics develops multi-specific antibodies for treating cancer and immune disorders. Biotech Series A $47.0M 2025-12-16 $89.0M Legend Capital, Gaorong Capital, BioVenture +2 11 to 50 2023
Phrontline Biopharma Phrontline Biopharma develops antibody-drug conjugate products to treat cancer. Biotech Seed $60.0M 2025-11-21 $73.8M Decheng Capital, Med-Fine Capital 11 to 50 2022
Brise Pharma Brise Pharma provides scientific research and technical services in the pharmaceutical field. Biotech Series A $28.1M 2025-11-11 $228.3M Qiming Venture Partners, Sherpa Healthcare Partners, BioTrack Capital +1 11 to 50 2021
GRIT Biotechnology GRIT Biotechnology develops tumor infiltrating lymphocyte immunotherapy for solid tumors. Biotech Series C $84.0M 2025-10-14 $153.5M Matrix Partners China, Hillhouse Investment, CICC +2 51 to 100 2019
Meiyou Technology Meiyou Technology develops DNA synthesizers using enzymatic technology for long-fragment DNA synthesis and splicing. Biotech Angel $1.4M 2024-06-28 MiraclePlus, Linear Capital, Danen Capital 11 to 50 2023

Table 1. Biotech startups in Shanghai, China: the 16 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 229.

Largest rounds

Last 12 months
10 rows
# Company What they do Sector Last round Amount Date Total raised Investors Employees Founded
1 CORXEL Pharmaceuticals CORXEL Pharmaceuticals develops medicines for underserved patients. Biotech Series D $287.0M 2026-01-22 $451.8M Leaps by Bayer, RTW Investments 51 to 100 2019
2 Full-Life Technologies Full-Life Technologies develops, produces, and commercializes medicines for cancer therapy. Biotech Series D $109.0M 2026-05-18 $337.3M Sky9 Capital, Chengwei Capital, Prosperity7 Ventures +1 51 to 100 2021
3 Bluesail Surgical Bluesail Surgical develops surgical instruments for cardiovascular treatments. Biotech Series B $104.5M 2026-09-23 $245.4M Huagai Capital, Linkong Private Equity Fund Management, Linqu County High-Tech Industrial Investment 101 to 250 2020
4 Phrontline Biopharma Phrontline Biopharma develops antibody-drug conjugate products to treat cancer. Biotech Seed $60.0M 2025-11-21 $73.8M Decheng Capital, Med-Fine Capital 11 to 50 2022
5 Bivision Bivision researches and develops targeted radiopharmaceuticals for therapy. Biotech Series B $58.8M 2026-05-18 $100.9M Gaorong Capital, Kaitai Capital, Lichen Capital 11 to 50 2021
6 Drug Farm Drug Farm develops therapies for infectious, immunological, and inflammatory diseases using genetics and artificial intelligence. Artificial intelligence Series D $55.0M 2026-07-13 $138.0M DT Capital Partners, South China Venture Capital, BVCF +1 101 to 250 2015
7 MindRank AI MindRank AI develops artificial intelligence platforms to discover and develop small molecule drugs. Artificial intelligence Series B $52.0M 2026-07-08 $101.0M Green Pine Capital Partners, Huagai Capital, Sherpa Healthcare Partners +1 11 to 50 2020
8 Allink Biotherapeutics Allink Biotherapeutics develops multi-specific antibodies for treating cancer and immune disorders. Biotech Series A $47.0M 2025-12-16 $89.0M Legend Capital, Gaorong Capital, BioVenture +2 11 to 50 2023
9 Novamab Novamab researches and develops new nanobodies. Biotech Series B $43.9M 2026-04-24 $97.8M Qiming Venture Partners, Taiyu Investment, Fuho Capital +1 51 to 100 2017
10 Degron Therapeutics Degron Therapeutics discovers molecular glue degraders for cancer treatment. Biotech Series A $40.0M 2026-05-14 $94.0M Baidu Ventures, BioVenture, New Alliance Capital +2 101 to 250 2021

Table 2. Biotech startups in Shanghai, China: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most active investors

By companies backed
#InvestorTypeLocation CompaniesShare Funded, 12 monthsLatest
1 Qiming Venture Partners Venture capital firm Shanghai, China 5 2% 1 Novamab
2 Sherpa Healthcare Partners Venture capital firm Beijing, China 4 2% 1 MindRank AI
3 MiraclePlus Startup accelerator Haidian, China 3 1% 1 SynMetaBio
4 Legend Capital Venture capital firm Beijing, China 3 1% 2 Alioth, Allink Biotherapeutics
5 Matrix Partners China Venture capital firm Beijing, China 3 1% 1 Alioth
6 Taiyu Investment Venture capital firm Beijing, China 3 1% 1 Novamab
7 BioVenture Venture capital firm Suzhou, China 2 1% 2 Degron Therapeutics, Allink Biotherapeutics
8 New Alliance Capital Private equity firm Shanghai, China 2 1% 1 Degron Therapeutics
9 Med-Fine Capital Venture capital firm Shanghai, China 2 1% 2 Degron Therapeutics, Phrontline Biopharma
10 Huagai Capital Private equity firm Beijing, China 2 1% 2 Bluesail Surgical, MindRank AI
11 Chengwei Capital Venture capital firm Shanghai, China 2 1% 1 Full-Life Technologies
12 Decheng Capital Venture capital firm Menlo Park, United States 2 1% 1 Phrontline Biopharma
13 Gaorong Capital Venture capital firm Wangjing, China 2 1% 2 Bivision, Allink Biotherapeutics
14 Kaitai Capital Venture capital firm Hangzhou, China 2 1% 1 Bivision
15 Linear Capital Venture capital firm Shanghai, China 2 1% 1 SynMetaBio

Table 3. Biotech startups in Shanghai, China: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Sectors

SectorsCompaniesShareTotal raised
Health care 194 85% $7.3B
Software 15 7% $532.1M
Artificial intelligence 13 6% $532.1M
Hardware 6 3%
Fintech 1 0%
Commerce 1 0%
Energy 1 0%

Table 4. Biotech startups in Shanghai, China by sector. Source: FundingWatcher. Data as of 16 November 2026.

Funding stage

Funding stageCompaniesShareMedian last round
Seed 51 22% $2.1M
Series A 76 33% $20.0M
Series B 53 23% $30.0M
Series C 29 13% $50.0M
Series D+ 20 9% $86.2M

Table 5. Biotech startups in Shanghai, China by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Rounds by month

Rounds by monthCompaniesShareRaised
November 2026 4 10% $99.5M
September 2026 5 12% $514.5M
August 2026 1 2%
July 2026 7 18% $190.4M
June 2026 1 2%
May 2026 5 12% $244.6M
April 2026 2 5% $58.5M
March 2026 3 8% $21.4M
February 2026 1 2%
January 2026 5 12% $315.7M
December 2025 5 12% $119.7M
November 2025 1 2% $60.0M

Table 6. Biotech startups in Shanghai, China: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most recent round by year

Most recent round by yearCompaniesShareRaised
2026 34 15% $1.4B
2025 34 15% $959.8M
2024 20 9% $62.7M
2023 26 11% $235.3M
2022 29 13% $738.1M
2021 35 15% $1.4B

Table 7. Biotech startups in Shanghai, China by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Founding year

Founding yearCompaniesShare
2023 or later 17 8%
2020 to 2022 68 30%
2015 to 2019 81 36%
2010 to 2014 39 17%
Before 2010 21 9%

Table 8. Biotech startups in Shanghai, China by founding year. Source: FundingWatcher. Data as of 16 November 2026.

Team size

Team sizeCompaniesShare
1 to 10 16 8%
11 to 50 81 41%
51 to 100 43 22%
101 to 250 27 14%
251 to 500 14 7%
501 to 1,000 9 5%
1,001 to 5,000 4 2%
5,001 to 10,000 2 1%

Table 9. Biotech startups in Shanghai, China by headcount. Source: FundingWatcher. Data as of 16 November 2026.

Method

Sources, fields and exclusions of both files: Method.

Questions

How many biotech startups in Shanghai, China are on the list?
229, in the file dated 16 November 2026. 40 of them closed their most recent round in the last 12 months.
What does the CSV contain?
One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
How much does the list cost?
$29 one-time for all 229 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
What arrives after payment?
At once: the CSV download link, on the page after payment and by mail.
Can I see rows before buying?
The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
How current is the data?
The file is dated 16 November 2026. The download link serves the current file each time it is opened.

Biotech startups in Shanghai, China: 229 rows, CSV, $29 one-time.

At once: the CSV download link, on the page after payment and by mail.

Columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.

With founder contacts: $199 one-time. List CSV right after payment; up to 2 verified founder or CEO emails per company compiled to order within 24 hours.

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

Biotech startups in Shanghai, China by funding stage

Other sectors in Shanghai

Biotech startups elsewhere

Cite: FundingWatcher, 229 funded biotech companies in Shanghai, China, 16 November 2026. https://fundingwatcher.com/startups/biotech/shanghai-shanghai/